1 4644 86 NEUROPATHIC PAIN TREATMENT: STILL A CHALLENGE. NEUROPATHIC PAIN (NP) IS THE RESULT OF A SERIES OF CONDITIONS CAUSED BY DISEASES OR LESIONS TO THE SOMATOSENSORY SYSTEM. DUE TO THE BETTER UNDERSTANDING OF NP PATHOPHYSIOLOGY PREVIOUSLY UNEXPLORED THERAPIES HAVE BEEN USED WITH ENCOURAGING RESULTS. IN THIS GROUP, ACETYL-L-CARNITINE, ALPHA-LIPOIC-ACID, CANNABINOIDS, CLONIDINE, EMA401, BOTULINUM TOXIN TYPE A AND NEW VOLTAGE-GATED SODIUM CHANNEL BLOCKERS, CAN BE INCLUDED. BESIDES, CHANGING PARADIGMS MAY OCCUR WITH THE ADVENT OF OPTOGENETICS AND A BETTER UNDERSTANDING OF EPIGENETIC REGULATION. WE REVIEWED THE PUBLISHED LITERATURE ON THE PHARMACOLOGICAL TREATMENT OF NP. DESPITE THE INTERESTING RESULTS, RANDOMIZED CONTROLLED TRIALS ARE DEMANDED THE MAJORITY OF THE THERAPIES PREVIOUSLY MENTIONED. IN SPITE OF SEVERAL STUDIES FOR THE RELIEF OF NP, PAIN CONTROL CONTINUES BEING A CHALLENGE. 2016 2 1881 71 EMERGING TREATMENTS FOR NEUROPATHIC PAIN. NEUROPATHIC PAIN IS A SERIES OF WELL-KNOWN CONDITIONS CAUSED BY DISEASES OR LESIONS TO THE SOMATOSENSORY SYSTEM. DUE TO THE BETTER UNDERSTANDING OF THE PATHOPHYSIOLOGY OF NEUROPATHIC PAIN, PREVIOUSLY UNEXPLORED THERAPIES HAVE BEEN USED WITH ENCOURAGING RESULTS. AS SUCH, ACETYL-L-CARNITINE (ALC), ALPHA-LIPOIC-ACID (ALA), CANNABINOIDS, CLONIDINE, EMA401, BOTULINUM TOXIN TYPE A, AND NEW VOLTAGE-GATED SODIUM CHANNEL BLOCKERS, CAN BE CITED. FURTHERMORE, NEW MODALITIES IN NEUROMODULATION SUCH AS HIGH-FREQUENCY SPINAL CORD STIMULATION, BURST STIMULATION, DORSAL ROOT GANGLION STIMULATION, TRANSCRANIAL DIRECT CURRENT STIMULATION, AND MANY OTHERS HAVE BEEN SHOWING EXCITING RESULTS. BESIDES, CHANGING PARADIGMS MAY OCCUR WITH THE ADVENT OF OPTOGENETICS AND A BETTER UNDERSTANDING OF EPIGENETIC REGULATION. THIS ARTICLE REVIEWS THE PUBLISHED LITERATURE ON THE TREATMENT OF NP. DESPITE THE INTERESTING RESULTS, RANDOMIZED CONTROLLED TRIALS ARE DEMANDED FOR THE MAJORITY OF THE THERAPIES PREVIOUSLY MENTIONED. 2015 3 2358 16 EPIGENETIC REGULATION OF RAC1 INDUCES SYNAPTIC REMODELING IN STRESS DISORDERS AND DEPRESSION. DEPRESSION INDUCES STRUCTURAL AND FUNCTIONAL SYNAPTIC PLASTICITY IN BRAIN REWARD CIRCUITS, ALTHOUGH THE MECHANISMS PROMOTING THESE CHANGES AND THEIR RELEVANCE TO BEHAVIORAL OUTCOMES ARE UNKNOWN. TRANSCRIPTIONAL PROFILING OF THE NUCLEUS ACCUMBENS (NAC) FOR RHO GTPASE-RELATED GENES, WHICH ARE KNOWN REGULATORS OF SYNAPTIC STRUCTURE, REVEALED A SUSTAINED REDUCTION IN RAS-RELATED C3 BOTULINUM TOXIN SUBSTRATE 1 (RAC1) EXPRESSION AFTER CHRONIC SOCIAL DEFEAT STRESS. THIS WAS ASSOCIATED WITH A REPRESSIVE CHROMATIN STATE SURROUNDING THE PROXIMAL PROMOTER OF RAC1. INHIBITION OF CLASS 1 HISTONE DEACETYLASES (HDACS) WITH MS-275 RESCUED BOTH THE DECREASE IN RAC1 TRANSCRIPTION AFTER SOCIAL DEFEAT STRESS AND DEPRESSION-RELATED BEHAVIOR, SUCH AS SOCIAL AVOIDANCE. WE FOUND A SIMILAR REPRESSIVE CHROMATIN STATE SURROUNDING THE RAC1 PROMOTER IN THE NAC OF SUBJECTS WITH DEPRESSION, WHICH CORRESPONDED WITH REDUCED RAC1 TRANSCRIPTION. VIRAL-MEDIATED REDUCTION OF RAC1 EXPRESSION OR INHIBITION OF RAC1 ACTIVITY IN THE NAC INCREASES SOCIAL DEFEAT-INDUCED SOCIAL AVOIDANCE AND ANHEDONIA IN MICE. CHRONIC SOCIAL DEFEAT STRESS INDUCES THE FORMATION OF STUBBY EXCITATORY SPINES THROUGH A RAC1-DEPENDENT MECHANISM INVOLVING THE REDISTRIBUTION OF SYNAPTIC COFILIN, AN ACTIN-SEVERING PROTEIN DOWNSTREAM OF RAC1. OVEREXPRESSION OF CONSTITUTIVELY ACTIVE RAC1 IN THE NAC OF MICE AFTER CHRONIC SOCIAL DEFEAT STRESS REVERSES DEPRESSION-RELATED BEHAVIORS AND PRUNES STUBBY SPINES. TAKEN TOGETHER, OUR DATA IDENTIFY EPIGENETIC REGULATION OF RAC1 IN THE NAC AS A DISEASE MECHANISM IN DEPRESSION AND REVEAL A FUNCTIONAL ROLE FOR RAC1 IN RODENTS IN REGULATING STRESS-RELATED BEHAVIORS. 2013 4 3236 21 HEN EGG LYSOZYME ALLEVIATES STATIC MECHANICAL PAIN VIA NRF1-PARKIN-TACAN SIGNALING AXIS IN SENSORY NEURONS. MECHANICAL ALLODYNIA IMPINGES ON THE LIFE QUALITY OF PATIENTS. HEN EGG LYSOZYME (HEL) IS A SUBSTANCE EXTRACTED FROM EGGS THAT IS COMMONLY USED TO INHIBIT BACTERIAL ACTIVITY. THE ROLE OF HEL IN REGULATING AND TREATING PAIN IS UNCLEAR. HERE, WE FIND THAT HEL SELECTIVELY ATTENUATES STATIC MECHANICAL ALLODYNIA OF MICE INDUCED BY COMPLETE FREUND'S ADJUVANT (CFA), SPINAL NERVE LIGATION (SNL) AND CHEMOTHERAPEUTIC AGENT. RNA-SEQ SCREENING REVEALS THAT CFA SIGNIFICANTLY REDUCES THE EXPRESSION OF PARKIN IN DORSAL ROOT GANGLION (DRG) NEURONS OF MICE, WHILE PRE-ADMINISTRATION OF HEL INCREASES THE EXPRESSION OF PARKIN AND REMITS THE STATIC MECHANICAL ALLODYNIA INDUCED BY PARKIN-SIRNA. MOREOVER, HEL INCREASES THE INTERACTION BETWEEN NUCLEAR RESPIRATORY FACTOR 1 (NRF1) AND HISTONE ACETYLTRANSFERASE P300 AND THEN ENHANCES THE NRF1 MEDIATED HISTONE ACETYLATION IN PRKN PROMOTER REGION IN DRGS OF MICE. FURTHER, PARKIN INTERACTS WITH MECHANOTRANSDUCING ION CHANNEL TACAN (TMEM120A) AND KNOCKDOWN OF PARKIN SIGNIFICANTLY INCREASES THE MEMBRANE TRAFFICKING OF TACAN IN SENSORY NEURONS OF MICE. WHILE PRE-ADMINISTRATION OF HEL INHIBITS THE INCREASED MEMBRANE TRAFFICKING OF TACAN IN SENSORY NEURONS OF MICE INDUCED BY PARKIN-SIRNA. IN ADDITION, PRE-GIVEN OF HEL ALSO SIGNIFICANTLY ATTENUATES THE STATIC MECHANICAL ALLODYNIA INDUCED BY OVEREXPRESSION OF TACAN IN MICE, AND THE EFFECT OF HEL CAN BE BLOCKED BY PARKIN-SIRNA. THIS INDICATES THAT HEL INCREASES THE EXPRESSION OF PARKIN THROUGH EPIGENETIC MECHANISMS AND THEN DECREASES TACAN MEMBRANE TRAFFICKING IN SENSORY NEURONS TO RELIEVE STATIC MECHANICAL HYPERSENSITIVITY. THEREFORE, WE REVEAL A NOVEL FUNCTION OF HEL, WHICH IS A POTENTIAL SUBSTANCE FOR THE TREATMENT OF STATIC MECHANICAL PAIN. 2022 5 1401 23 DIETARY AND PHARMACOLOGICAL TREATMENT OF ABDOMINAL PAIN IN IBS. THIS REVIEW INTRODUCES THE PRINCIPLES OF VISCERAL SENSATION AND APPRAISES THE CURRENT APPROACHES TO MANAGEMENT OF VISCERAL PAIN IN FUNCTIONAL GI DISEASES, PRINCIPALLY IBS. THESE APPROACHES INCLUDE DIETARY MEASURES INCLUDING FIBRE SUPPLEMENTATION, LOW FERMENTABLE OLIGOSACCHARIDES, DISACCHARIDES, MONOSACCHARIDES AND POLYOLS DIET, AND PHARMACOLOGICAL APPROACHES SUCH AS ANTISPASMODICS, PEPPERMINT OIL, ANTIDEPRESSANTS (TRICYCLIC AGENTS, SELECTIVE SEROTONIN REUPTAKE INHIBITORS), 5-HT(3) RECEPTOR ANTAGONISTS (ALOSETRON, ONDANSETRON, RAMOSETRON), NON-ABSORBED ANTIBIOTIC (RIFAXIMIN), SECRETAGOGUES (LUBIPROSTONE, LINACLOTIDE), MU-OPIOID RECEPTOR (OR) AND KAPPA-OR AGONIST, DELTA-OR ANTAGONIST (ELUXADOLINE), HISTAMINE H1 RECEPTOR ANTAGONIST (EBASTINE), NEUROKININ-2 RECEPTOR ANTAGONIST (IBODUTANT) AND GABAERGIC AGENTS (GABAPENTIN AND PREGABALIN). EFFICACY AND SAFETY ARE DISCUSSED BASED ON PIVOTAL TRIALS OR PUBLISHED SYSTEMATIC REVIEWS AND META-ANALYSIS, EXPRESSING ORS OR RELATIVE RISKS AND THEIR 95% CIS. POTENTIAL NEW APPROACHES MAY BE BASED ON RECENT INSIGHTS ON MUCOSAL EXPRESSION OF GENES, AND MICRORNA AND EPIGENETIC MARKERS IN HUMAN BIOPSIES AND IN ANIMAL MODELS OF VISCERAL HYPERSENSITIVITY.THE OBJECTIVES OF THIS REVIEW ARE TO APPRAISE THE PHYSIOLOGY AND ANATOMY OF GUT SENSATION AND THE EFFICACY IN THE RELIEF OF VISCERAL PAIN (TYPICALLY IN IBS) OF SEVERAL CLASSES OF THERAPIES. THESE INCLUDE FERMENTABLE OLIGOSACCHARIDES, DISACCHARIDES, MONOSACCHARIDES AND POLYOLS (FODMAPS) AND DIFFERENT CLASSES OF MEDICATIONS (BOX 1). BOX 1CLASSES OF PHARMACOLOGICAL AGENTS FOR VISCERAL PAINANTIDEPRESSANTS (TRICYCLIC AGENTS, SELECTIVE SEROTONIN REUPTAKE INHIBITORS)PEPPERMINT OIL5-HT(3) RECEPTOR ANTAGONISTS (ALOSETRON, ONDANSETRON, RAMOSETRON)NON-ABSORBED ANTIBIOTIC (RIFAXIMIN)SECRETAGOGUES (LUBIPROSTONE, LINACLOTIDE)MU-OPIOID RECEPTOR (OR) AND KAPPA-OR AGONIST AND DELTA-OR ANTAGONIST (ELUXADOLINE)HISTAMINE H1 RECEPTOR ANTAGONIST (EBASTINE)NEUROKININ-2 RECEPTOR ANTAGONIST (IBODUTANT)GABAERGIC AGENTS (GABAPENTIN AND PREGABALIN). 2017 6 967 17 CHRONIC NICOTINE EXPOSURE AUGMENTS RENAL OXIDATIVE STRESS AND INJURY THROUGH TRANSCRIPTIONAL ACTIVATION OF P66SHC. BACKGROUND: CHRONIC NICOTINE (CH-NIC) EXPOSURE EXACERBATES ISCHEMIA/REPERFUSION (I/R)-INDUCED OXIDATIVE STRESS AND ACUTE KIDNEY INJURY (AKI), AND MITOCHONDRIAL PRODUCTION OF REACTIVE OXYGEN SPECIES (ROS) IN CULTURED RENAL PROXIMAL TUBULE CELLS (RPTCS). BECAUSE SER36-PHOSPHORYLATED P66SHC MODULATES MITOCHONDRIAL ROS PRODUCTION AND INJURY OF RPTCS, WE HYPOTHESIZED THAT CH-NIC EXACERBATES AKI BY INCREASING STRESS-INDUCED PHOSPHORYLATION OF P66SHC. METHODS: WE FIRST TESTED WHETHER CH-NIC AUGMENTS I/R-AKI-INDUCED EXPRESSION AND PHOSPHORYLATION OF P66SHC IN VIVO. WE THEN EXAMINED WHETHER KNOCKING DOWN P66SHC, OR IMPAIRING ITS SER36 PHOSPHORYLATION OR BINDING TO CYTOCHROME C, ALTERS THE EFFECTS OF CH-NIC ON OXIDATIVE STRESS (H(2)O(2))-INDUCED PRODUCTION OF ROS, MITOCHONDRIAL DEPOLARIZATION AND INJURY IN RPTCS IN VITRO. RESULTS: WE FOUND THAT CH-NIC INCREASED THE EXPRESSION OF P66SHC IN THE CONTROL AND ISCHEMIC KIDNEYS, BUT ONLY INCREASED ITS SER36 PHOSPHORYLATION AFTER RENAL I/R. KNOCKING DOWN P66SHC OR IMPAIRING PHOSPHORYLATION OF ITS SER36 RESIDUE, VIA THE S36A MUTATION (BUT NOT THE PHOSPHOMIMETIC S36D MUTATION), BLUNTED CH-NIC + H2O2-DEPENDENT ROS PRODUCTION, MITOCHONDRIAL DEPOLARIZATION AND INJURY IN RPTCS. ADDITIONALLY, CH-NIC + H2O2-DEPENDENT BINDING OF P66SHC TO MITOCHONDRIAL CYTOCHROME C WAS ATTENUATED BY S36A MUTATION OF P66SHC, AND IMPAIRING CYTOCHROME C BINDING (VIA W134F MUTATION) ABOLISHED ROS PRODUCTION, MITOCHONDRIAL DEPOLARIZATION AND INJURY, WHILE ECTOPIC OVEREXPRESSION OF P66SHC (WHICH MIMICS CH-NIC TREATMENT) AUGMENTED OXIDANT INJURY. WE DETERMINED THAT CH-NIC STIMULATES THE P66SHC PROMOTER THROUGH P53- AND EPIGENETIC MODIFICATION (PROMOTER HYPOMETHYLATION). CONCLUSIONS: CH-NIC WORSENS OXIDATIVE STRESS-DEPENDENT ACUTE RENAL INJURY BY INCREASING EXPRESSION AND CONSEQUENT OXIDATIVE STRESS-DEPENDENT SER36 PHOSPHORYLATION OF P66SHC. THUS, TARGETING THIS PATHWAY MAY HAVE THERAPEUTIC RELEVANCE IN PREVENTING/AMELIORATING TOBACCO-RELATED KIDNEY INJURY. 2013 7 3626 20 IN-SILICO DISCOVERY OF DUAL ACTIVE MOLECULE TO RESTORE SYNAPTIC WIRING AGAINST AUTISM SPECTRUM DISORDER VIA HDAC2 AND H3R INHIBITION. METAL-DEPENDENT HISTONE DEACETYLASES (HDACS) ARE ESSENTIAL EPIGENETIC REGULATORS; THEIR MOLECULAR AND PHARMACOLOGICAL ROLES IN MEDICALLY CRITICAL DISEASES SUCH AS NEUROPSYCHIATRIC DISORDERS, NEURODEGENERATION, AND CANCER ARE BEING STUDIED GLOBALLY. HDAC2'S DIFFERENTIAL EXPRESSION IN THE CENTRAL NERVOUS SYSTEM MAKES IT AN APPEALING THERAPEUTIC TARGET FOR CHRONIC NEUROLOGICAL DISEASES LIKE AUTISM SPECTRUM DISORDER. IN THIS STUDY, WE IDENTIFIED H3R INHIBITOR MOLECULES THAT ARE COMPUTATIONALLY EFFECTIVE AT BINDING TO THE HDAC2 METAL-COORDINATED BINDING SITE. THE STUDY HIGHLIGHTS THE IMPORTANCE OF PITOLISANT IN SCREENING THE POTENTIAL H3R INHIBITORS BY USING A HYBRID WORKFLOW OF LIGAND AND RECEPTOR-BASED DRUG DISCOVERY. THE SCREENED LEAD COMPOUNDS WITH PUBCHEM SIDS 103179850, 103185945, AND 103362074 SHOW VIABLE BINDING WITH HDAC2 IN SILICO. THE IMPORTANCE OF LIGAND CONTACTS WITH THE ZN2+ ION IN THE HDAC2 CATALYTIC SITE IS ALSO DISCUSSED AND INVESTIGATED FOR A SIGNIFICANT ROLE IN ENZYME INHIBITION. THE PROPOSED H3R INHIBITORS 103179850, 103185945, AND 103362074 ARE ESTIMATED AS DUAL-ACTIVE MOLECULES TO BLOCK THE HDAC2-MEDIATED DEACETYLATION OF THE EAAT2 GENE (SLC1A2) AND H3R-MEDIATED SYNAPTIC TRANSMISSION IRREGULARITY AND ARE, THEREFORE, OPEN FOR EXPERIMENTAL VALIDATION. 2022 8 5763 15 SOME COMMENTS ON MASOCHISM AND THE DELUSION OF OMNIPOTENCE FROM A DEVELOPMENTAL PERSPECTIVE. THIS PAPER EXPLORES THE RELATION OF THE DELUSION OF OMNIPOTENCE TO MASOCHISM AND SUGGESTS THAT THIS FANTASY CONSTITUTES A MAJOR COMPONENT OF THE RESISTANCE SO PROMINENT IN WORK WITH MASOCHISTIC PATIENTS. THE CONNECTIONS AMONG MASOCHISM, OMNIPOTENCE, NEGATIVE THERAPEUTIC REACTION, AND CLINGING TO PAIN ARE DISCUSSED. THE CLASSICAL VIEW HAS BEEN THAT THE FAILURE OF INFANTILE OMNIPOTENCE FORCES THE CHILD TO TURN TO REALITY. OUR EXPERIENCE WITH MASOCHISTIC PATIENTS SUGGESTS THAT IT IS THE REAL FAILURE TO ACHIEVE COMPETENT INTERACTIONS WITH OTHERS THAT FORCES THE CHILD TO TURN TO OMNIPOTENT SOLUTIONS. THE DISTINCTION IS MADE BETWEEN FANTASIES THAT ENHANCE THE REAL CAPACITIES OF THE SELF AND THOSE AIMED AT DENYING AND TRANSFORMING THE PAIN AND INADEQUACY OF THE MOTHER-CHILD RELATIONSHIP. THE EPIGENETIC TRANSFORMATIONS OF OMNIPOTENT FANTASIES THROUGH ALL LEVELS OF DEVELOPMENT ARE DESCRIBED. THE PATIENT'S NEED TO PROTECT THE OMNIPOTENT FANTASY IS DISCUSSED IN RELATION TO RESISTANCE AT EACH PHASE OF ANALYSIS. 1991 9 2796 12 FBW7 MEDIATES SENESCENCE AND PULMONARY FIBROSIS THROUGH TELOMERE UNCAPPING. TISSUE STEM CELLS UNDERGO PREMATURE SENESCENCE UNDER STRESS, PROMOTING AGE-RELATED DISEASES; HOWEVER, THE ASSOCIATED MECHANISMS REMAIN UNCLEAR. HERE, WE REPORT THAT IN RESPONSE TO RADIATION, OXIDATIVE STRESS, OR BLEOMYCIN, THE E3 UBIQUITIN LIGASE FBW7 MEDIATES CELL SENESCENCE AND TISSUE FIBROSIS THROUGH TELOMERE UNCAPPING. FBW7 BINDING TO TELOMERE PROTECTION PROTEIN 1 (TPP1) FACILITATES TPP1 MULTISITE POLYUBIQUITINATION AND ACCELERATES DEGRADATION, TRIGGERING TELOMERE UNCAPPING AND DNA DAMAGE RESPONSE. OVEREXPRESSING TPP1 OR INHIBITING FBW7 BY GENETIC ABLATION, EPIGENETIC INTERFERENCE, OR PEPTIDOMIMETIC TELOMERE DYSFUNCTION INHIBITOR (TELODIN) REDUCES TELOMERE UNCAPPING AND SHORTENING, EXPANDING THE PULMONARY ALVEOLAR AEC2 STEM CELL POPULATION IN MICE. TELODIN, SYNTHESIZED FROM THE SEVENTH BETA STRAND BLADE OF FBW7 WD40 PROPELLER DOMAIN, INCREASES TPP1 STABILITY, LUNG RESPIRATORY FUNCTION, AND RESISTANCE TO SENESCENCE AND FIBROSIS IN ANIMALS CHRONICALLY EXPOSED TO ENVIRONMENTAL STRESS. OUR FINDINGS ELUCIDATE A PIVOTAL MECHANISM UNDERLYING STRESS-INDUCED PULMONARY EPITHELIAL STEM CELL SENESCENCE AND FIBROSIS, PROVIDING A FRAMEWORK FOR AGING-RELATED DISORDER INTERVENTIONS. 2020 10 6256 20 THE MITOGEN AND STRESS-ACTIVATED PROTEIN KINASE 1 REGULATES THE RAPID EPIGENETIC TAGGING OF DORSAL HORN NEURONS AND NOCIFENSIVE BEHAVIOUR. PHOSPHORYLATION OF HISTONE H3 AT SERINE 10 (P-H3S10) IS A MARKER OF ACTIVE GENE TRANSCRIPTION. USING COGNITIVE MODELS OF NEURAL PLASTICITY, P-H3S10 WAS SHOWN TO BE DOWNSTREAM OF EXTRACELLULAR SIGNAL-REGULATED KINASE (ERK) SIGNALLING IN THE HIPPOCAMPUS. IN THIS STUDY, WE SHOW THAT NOCICEPTIVE SIGNALLING AFTER PERIPHERAL FORMALIN INJECTION INCREASED P-H3S10 EXPRESSION IN THE IPSILATERAL DORSAL HORN. THIS INCREASE WAS MAXIMAL 30 MINUTES AFTER FORMALIN INJECTION AND OCCURRED MAINLY WITHIN P-ERK-POSITIVE NEURONS. SPINAL P-H3S10-ENHANCED EXPRESSION WAS ALSO OBSERVED IN NEUROKININ 1 RECEPTOR (NK1R), C-FOS, AND ZIF268 POSITIVE NEURONS AND WAS INHIBITED BY ABLATION OF SEROTONERGIC DESCENDING CONTROLS. THE MITOGEN AND STRESS-ACTIVATED PROTEIN KINASE 1 (MSK1) IS DOWNSTREAM OF ERK AND CAN INDUCE P-H3S10. WE FOUND THAT, AFTER FORMALIN INJECTION, MOST PHOSPHO-MSK1 (P-MSK1)-POSITIVE CELLS (87% +/- 3%) EXPRESSED P-ERK AND THE MAJORITY OF P-H3S10-POSITIVE CELLS (85% +/- 5%) EXPRESSED P-MSK1. INHIBITION OF ERK ACTIVITY WITH THE MEK INHIBITOR SL327 REDUCED FORMALIN-INDUCED P-ERK, P-MSK1, AND P-H3S10, DEMONSTRATING THAT SPINAL P-MSK1 AND P-H3S10 WERE AT LEAST PARTLY DOWNSTREAM OF ERK SIGNALLING. CRUCIALLY, PHARMACOLOGICAL BLOCKADE OF SPINAL MSK1 ACTIVITY WITH THE NOVEL MSK1 INHIBITOR SB727651A INHIBITED FORMALIN-INDUCED SPINAL P-H3S10 AND NOCIFENSIVE BEHAVIOUR. THESE FINDINGS ARE THE FIRST TO ESTABLISH THE INVOLVEMENT OF P-H3S10 AND ITS MAIN KINASE, MSK1, IN ERK REGULATION OF NOCICEPTION. GIVEN THE GENERAL IMPORTANCE OF ERK SIGNALLING IN PAIN PROCESSING, OUR RESULTS SUGGEST THAT P-H3S10 COULD PLAY A ROLE IN THE RESPONSE TO INJURY. 2016 11 4508 15 MS-11, A MIMETIC OF THE MSIN3-BINDING HELIX IN NRSF, AMELIORATES SOCIAL INTERACTION DEFICITS IN A PRENATAL VALPROIC ACID-INDUCED AUTISM MOUSE MODEL. GROWING EVIDENCE SUGGESTS PIVOTAL ROLES FOR EPIGENETIC MECHANISMS IN BOTH ANIMAL MODELS OF AND INDIVIDUALS WITH AUTISM SPECTRUM DISORDERS (ASD). NEURON-RESTRICTIVE SILENCER FACTOR (NRSF) BINDS TO NEURON-RESTRICTIVE SILENCING ELEMENTS IN NEURONAL GENES AND RECRUITS CO-REPRESSORS, SUCH AS MSIN3, TO EPIGENETICALLY INHIBIT NEURONAL GENE EXPRESSION. BECAUSE DYSREGULATION OF NRSF IS RELATED TO ASD, HERE WE EXAMINED THE EFFECTS OF MS-11, A CHEMICALLY OPTIMIZED MIMETIC OF THE MSIN3-BINDING HELIX IN NRSF, ON THE BEHAVIORAL AND MORPHOLOGICAL ABNORMALITIES FOUND IN A MOUSE MODEL OF VALPROIC ACID (VPA)-INDUCED ASD. CHRONIC TREATMENT WITH MS-11 IMPROVED PRENATAL VPA-INDUCED DEFICITS IN SOCIAL INTERACTION. ADDITIONALLY, WE FOUND THAT NRSF MRNA EXPRESSION WAS GREATER IN THE SOMATOSENSORY CORTEX OF VPA-EXPOSED MICE THAN OF CONTROLS. AGREEING WITH THESE BEHAVIORAL FINDINGS, MICE THAT WERE PRENATALLY EXPOSED TO VPA SHOWED LOWER DENDRITIC SPINE DENSITY IN THE SOMATOSENSORY CORTEX, WHICH WAS REVERSED BY CHRONIC TREATMENT WITH MS-11. THESE FINDINGS SUGGEST THAT MS-11 HAS THE POTENTIAL FOR IMPROVING ASD-RELATED SYMPTOMS THROUGH INHIBITION OF MSIN3-NRSF BINDING. 2019 12 5503 18 RGS9-2--CONTROLLED ADAPTATIONS IN THE STRIATUM DETERMINE THE ONSET OF ACTION AND EFFICACY OF ANTIDEPRESSANTS IN NEUROPATHIC PAIN STATES. THE STRIATAL PROTEIN REGULATOR OF G-PROTEIN SIGNALING 9-2 (RGS9-2) PLAYS A KEY MODULATORY ROLE IN OPIOID, MONOAMINE, AND OTHER G-PROTEIN-COUPLED RECEPTOR RESPONSES. HERE, WE USE THE MURINE SPARED-NERVE INJURY MODEL OF NEUROPATHIC PAIN TO INVESTIGATE THE MECHANISM BY WHICH RGS9-2 IN THE NUCLEUS ACCUMBENS (NAC), A BRAIN REGION INVOLVED IN MOOD, REWARD, AND MOTIVATION, MODULATES THE ACTIONS OF TRICYCLIC ANTIDEPRESSANTS (TCAS). PREVENTION OF RGS9-2 ACTION IN THE NAC INCREASES THE EFFICACY OF THE TCA DESIPRAMINE AND DRAMATICALLY ACCELERATES ITS ONSET OF ACTION. BY CONTROLLING THE ACTIVATION OF EFFECTOR MOLECULES BY G PROTEIN ALPHA AND BETAGAMMA SUBUNITS, RGS9-2 AFFECTS SEVERAL PROTEIN INTERACTIONS, PHOSPHOPROTEIN LEVELS, AND THE FUNCTION OF THE EPIGENETIC MODIFIER HISTONE DEACETYLASE 5, WHICH ARE IMPORTANT FOR TCA RESPONSIVENESS. FURTHERMORE, INFORMATION FROM RNA-SEQUENCING ANALYSIS REVEALS THAT RGS9-2 IN THE NAC AFFECTS THE EXPRESSION OF MANY GENES KNOWN TO BE INVOLVED IN NOCICEPTION, ANALGESIA, AND ANTIDEPRESSANT DRUG ACTIONS. OUR FINDINGS PROVIDE NOVEL INFORMATION ON NAC-SPECIFIC CELLULAR MECHANISMS THAT MEDIATE THE ACTIONS OF TCAS IN NEUROPATHIC PAIN STATES. 2015 13 4669 22 NEW INSIGHTS INTO PATHOPHYSIOLOGY OF VESTIBULAR MIGRAINE. VESTIBULAR MIGRAINE (VM) IS A COMMON DISORDER IN WHICH GENETIC, EPIGENETIC, AND ENVIRONMENTAL FACTORS PROBABLY CONTRIBUTE TO ITS DEVELOPMENT. THE PATHOPHYSIOLOGY OF VM IS UNKNOWN; NEVERTHELESS IN THE LAST FEW YEARS, SEVERAL STUDIES ARE CONTRIBUTING TO UNDERSTAND THE NEUROPHYSIOLOGICAL PATHWAYS INVOLVED IN VM. THE CURRENT HYPOTHESES ARE MOSTLY BASED ON THE KNOWLEDGE OF MIGRAINE ITSELF. THE EVIDENCE OF TRIGEMINAL INNERVATION OF THE LABYRINTH VESSELS AND THE LOCALIZATION OF VASOACTIVE NEUROPEPTIDES IN THE PERIVASCULAR AFFERENT TERMINALS OF THESE TRIGEMINAL FIBERS SUPPORT THE INVOLVEMENT OF THE TRIGEMINO-VASCULAR SYSTEM. THE NEUROGENIC INFLAMMATION TRIGGERED BY ACTIVATION OF THE TRIGEMINAL-VESTIBULOCOCHLEAR REFLEX, WITH THE SUBSEQUENT INNER EAR PLASMA PROTEIN EXTRAVASATION AND THE RELEASE OF INFLAMMATORY MEDIATORS, CAN CONTRIBUTE TO A SUSTAINED ACTIVATION AND SENSITIZATION OF THE TRIGEMINAL PRIMARY AFFERENT NEURONS EXPLAINING VM SYMPTOMS. THE RECIPROCAL CONNECTIONS BETWEEN BRAINSTEM VESTIBULAR NUCLEI AND THE STRUCTURES THAT MODULATE TRIGEMINAL NOCICEPTIVE INPUTS (ROSTRAL VENTROMEDIAL MEDULLA, VENTROLATERAL PERIAQUEDUCTAL GRAY, LOCUS COERULEUS, AND NUCLEUS RAPHE MAGNUS) ARE CRITICAL TO UNDERSTAND THE PATHOPHYSIOLOGY OF VM. ALTHOUGH CORTICAL SPREADING DEPRESSION CAN AFFECT CORTICAL AREAS INVOLVED IN PROCESSING VESTIBULAR INFORMATION, FUNCTIONAL NEUROIMAGING TECHNIQUES SUGGEST A DYSMODULATION IN THE MULTIMODAL SENSORY INTEGRATION AND PROCESSING OF VESTIBULAR AND NOCICEPTIVE INFORMATION, RESULTING FROM A VESTIBULO-THALAMO-CORTICAL DYSFUNCTION, AS THE PATHOGENIC MECHANISM UNDERLYING VM. THE ELEVATED PREVALENCE OF VM SUGGESTS THAT MULTIPLE FUNCTIONAL VARIANTS MAY CONFER A GENETIC SUSCEPTIBILITY LEADING TO A DYSREGULATION OF EXCITATORY-INHIBITORY BALANCE IN BRAIN STRUCTURES INVOLVED IN THE PROCESSING OF SENSORY INFORMATION, VESTIBULAR INPUTS, AND PAIN. THE INTERACTIONS AMONG SEVERAL FUNCTIONAL AND STRUCTURAL NEURAL NETWORKS COULD EXPLAIN THE PATHOGENIC MECHANISMS OF VM. 2015 14 3368 20 HISTONE METHYLTRANSFERASE G9A DIMINISHES EXPRESSION OF CANNABINOID CB(1) RECEPTORS IN PRIMARY SENSORY NEURONS IN NEUROPATHIC PAIN. TYPE 1 CANNABINOID RECEPTORS (CB(1)RS) ARE EXPRESSED IN THE DORSAL ROOT GANGLION (DRG) AND CONTRIBUTE TO THE ANALGESIC EFFECT OF CANNABINOIDS. HOWEVER, THE EPIGENETIC MECHANISM REGULATING THE EXPRESSION OF CB(1)RS IN NEUROPATHIC PAIN IS UNKNOWN. G9A (ENCODED BY THE EHMT2 GENE), A HISTONE 3 AT LYSINE 9 METHYLTRANSFERASE, IS A KEY CHROMATIN REGULATOR RESPONSIBLE FOR GENE SILENCING. IN THIS STUDY, WE DETERMINED G9A'S ROLE IN REGULATING CB(1)R EXPRESSION IN THE DRG AND IN CB(1)R-MEDIATED ANALGESIC EFFECTS IN AN ANIMAL MODEL OF NEUROPATHIC PAIN. WE SHOW THAT NERVE INJURY PROFOUNDLY REDUCED MRNA LEVELS OF CB(1)RS BUT INCREASED THE EXPRESSION OF CB(2) RECEPTORS IN THE RAT DRG. CHIP RESULTS INDICATED INCREASED ENRICHMENT OF HISTONE 3 AT LYSINE 9 DIMETHYLATION, A G9A-CATALYZED REPRESSIVE HISTONE MARK, AT THE PROMOTER REGIONS OF THE CB(1)R GENES. G9A INHIBITION IN NERVE-INJURED RATS NOT ONLY UP-REGULATED THE CB(1)R EXPRESSION LEVEL IN THE DRG BUT ALSO POTENTIATED THE ANALGESIC EFFECT OF A CB(1)R AGONIST ON NERVE INJURY-INDUCED PAIN HYPERSENSITIVITY. FURTHERMORE, IN MICE LACKING EHMT2 IN DRG NEURONS, NERVE INJURY FAILED TO REDUCE CB(1)R EXPRESSION IN THE DRG AND TO DECREASE THE ANALGESIC EFFECT OF THE CB(1)R AGONIST. MOREOVER, NERVE INJURY DIMINISHED THE INHIBITORY EFFECT OF THE CB(1)R AGONIST ON SYNAPTIC GLUTAMATE RELEASE FROM PRIMARY AFFERENT NERVES TO SPINAL CORD DORSAL HORN NEURONS IN WT MICE BUT NOT IN MICE LACKING EHMT2 IN DRG NEURONS. OUR FINDINGS REVEAL THAT NERVE INJURY DIMINISHES THE ANALGESIC EFFECT OF CB(1)R AGONISTS THROUGH G9A-MEDIATED CB(1)R DOWN-REGULATION IN PRIMARY SENSORY NEURONS. 2020 15 55 29 A GAIN-OF-FUNCTION SODIUM CHANNEL BETA2-SUBUNIT MUTATION IN PAINFUL DIABETIC NEUROPATHY. DIABETES MELLITUS IS A GLOBAL CHALLENGE WITH MANY DIVERSE HEALTH SEQUELAE, OF WHICH DIABETIC PERIPHERAL NEUROPATHY IS ONE OF THE MOST COMMON. A SUBSTANTIAL NUMBER OF PATIENTS WITH DIABETIC PERIPHERAL NEUROPATHY DEVELOP CHRONIC PAIN, BUT THE GENETIC AND EPIGENETIC FACTORS THAT PREDISPOSE DIABETIC PERIPHERAL NEUROPATHY PATIENTS TO DEVELOP NEUROPATHIC PAIN ARE POORLY UNDERSTOOD. RECENT TARGETED GENETIC STUDIES HAVE IDENTIFIED MUTATIONS IN ALPHA-SUBUNITS OF VOLTAGE-GATED SODIUM CHANNELS (NA(V)S) IN PATIENTS WITH PAINFUL DIABETIC PERIPHERAL NEUROPATHY. MUTATIONS IN PROTEINS THAT REGULATE TRAFFICKING OR FUNCTIONAL PROPERTIES OF NA(V)S COULD EXPAND THE SPECTRUM OF PATIENTS WITH NA(V)-RELATED PERIPHERAL NEUROPATHIES. THE AUXILIARY SODIUM CHANNEL BETA-SUBUNITS (BETA1-4) HAVE BEEN REPORTED TO INCREASE CURRENT DENSITY, ALTER INACTIVATION KINETICS, AND MODULATE SUBCELLULAR LOCALIZATION OF NA(V). MUTATIONS IN BETA-SUBUNITS HAVE BEEN ASSOCIATED WITH SEVERAL DISEASES, INCLUDING EPILEPSY, CANCER, AND DISEASES OF THE CARDIAC CONDUCTING SYSTEM. HOWEVER, MUTATIONS IN BETA-SUBUNITS HAVE NEVER BEEN SHOWN PREVIOUSLY TO CONTRIBUTE TO NEUROPATHIC PAIN. WE REPORT HERE A PATIENT WITH PAINFUL DIABETIC PERIPHERAL NEUROPATHY AND NEGATIVE GENETIC SCREENING FOR MUTATIONS IN SCN9A, SCN10A, AND SCN11A-GENES ENCODING SODIUM CHANNEL ALPHA-SUBUNIT THAT HAVE BEEN PREVIOUSLY LINKED TO THE DEVELOPMENT OF NEUROPATHIC PAIN. GENETIC ANALYSIS REVEALED AN ASPARTIC ACID TO ASPARAGINE MUTATION, D109N, IN THE BETA2-SUBUNIT. FUNCTIONAL ANALYSIS USING CURRENT-CLAMP REVEALED THAT THE BETA2-D109N RENDERED DORSAL ROOT GANGLION NEURONS HYPEREXCITABLE, ESPECIALLY IN RESPONSE TO REPETITIVE STIMULATION. UNDERLYING THE HYPEREXCITABILITY INDUCED BY THE BETA2-SUBUNIT MUTATION, AS EVIDENCED BY VOLTAGE-CLAMP ANALYSIS, WE FOUND A DEPOLARIZING SHIFT IN THE VOLTAGE DEPENDENCE OF NA(V)1.7 FAST INACTIVATION AND REDUCED USE-DEPENDENT INHIBITION OF THE NA(V)1.7 CHANNEL. 2019 16 4919 19 PANNEXIN-1 UP-REGULATION IN THE DORSAL ROOT GANGLION CONTRIBUTES TO NEUROPATHIC PAIN DEVELOPMENT. PANNEXIN-1 (PANX1) IS A LARGE-PORE MEMBRANE CHANNEL INVOLVED IN THE RELEASE OF ATP AND OTHER SIGNALING MEDIATORS. LITTLE IS KNOWN ABOUT THE EXPRESSION AND FUNCTIONAL ROLE OF PANX1 IN THE DORSAL ROOT GANGLION (DRG) IN THE DEVELOPMENT OF CHRONIC NEUROPATHIC PAIN. IN THIS STUDY, WE DETERMINED THE EPIGENETIC MECHANISM INVOLVED IN INCREASED PANX1 EXPRESSION IN THE DRG AFTER NERVE INJURY. SPINAL NERVE LIGATION IN RATS SIGNIFICANTLY INCREASED THE MRNA AND PROTEIN LEVELS OF PANX1 IN THE DRG BUT NOT IN THE SPINAL CORD. IMMUNOCYTOCHEMICAL LABELING SHOWED THAT PANX1 WAS PRIMARILY EXPRESSED IN A SUBSET OF MEDIUM AND LARGE DRG NEURONS IN CONTROL RATS AND THAT NERVE INJURY MARKEDLY INCREASED THE NUMBER OF PANX1-IMMUNOREACTIVE DRG NEURONS. NERVE INJURY SIGNIFICANTLY INCREASED THE ENRICHMENT OF TWO ACTIVATING HISTONE MARKS (H3K4ME2 AND H3K9AC) AND DECREASED THE OCCUPANCY OF TWO REPRESSIVE HISTONE MARKS (H3K9ME2 AND H3K27ME3) AROUND THE PROMOTER REGION OF PANX1 IN THE DRG. HOWEVER, NERVE INJURY HAD NO EFFECT ON THE DNA METHYLATION LEVEL AROUND THE PANX1 PROMOTER IN THE DRG. FURTHERMORE, INTRATHECAL INJECTION OF THE PANX1 BLOCKERS OR PANX1-SPECIFIC SIRNA SIGNIFICANTLY REDUCED PAIN HYPERSENSITIVITY INDUCED BY NERVE INJURY. IN ADDITION, SIRNA KNOCKDOWN OF PANX1 EXPRESSION IN A DRG CELL LINE SIGNIFICANTLY REDUCED CASPASE-1 RELEASE INDUCED BY NEURONAL DEPOLARIZATION. OUR FINDINGS SUGGEST THAT NERVE INJURY INCREASES PANX1 EXPRESSION LEVELS IN THE DRG THROUGH ALTERED HISTONE MODIFICATIONS. PANX1 UP-REGULATION CONTRIBUTES TO THE DEVELOPMENT OF NEUROPATHIC PAIN AND STIMULATION OF INFLAMMASOME SIGNALING. 2015 17 2819 18 FILARIAL AND WOLBACHIA GENOMICS. FILARIAL NEMATODE PARASITES, THE CAUSATIVE AGENTS FOR A SPECTRUM OF ACUTE AND CHRONIC DISEASES INCLUDING LYMPHATIC FILARIASIS AND RIVER BLINDNESS, THREATEN THE WELL-BEING AND LIVELIHOOD OF HUNDREDS OF MILLIONS OF PEOPLE IN THE DEVELOPING REGIONS OF THE WORLD. THE 2007 PUBLICATION ON A DRAFT ASSEMBLY OF THE 95-MB GENOME OF THE HUMAN FILARIAL PARASITE BRUGIA MALAYI- REPRESENTING THE FIRST HELMINTH PARASITE GENOME TO BE SEQUENCED - HAS BEEN FOLLOWED IN RAPID SUCCESSION BY PROJECTS THAT HAVE RESULTED IN THE GENOME SEQUENCING OF SIX ADDITIONAL FILARIAL SPECIES, SEVEN NONFILARIAL NEMATODE PARASITES OF ANIMALS AND NEARLY 30 PLANT PARASITIC AND FREE-LIVING SPECIES. PARALLEL TO THE GENOMIC SEQUENCING, TRANSCRIPTOMIC AND PROTEOMIC PROJECTS HAVE FACILITATED GENOME ANNOTATION, EXPANDED OUR UNDERSTANDING OF STAGE-ASSOCIATED GENE EXPRESSION AND PROVIDED A FIRST LOOK AT THE ROLE OF EPIGENETIC REGULATION OF FILARIAL GENOMES THROUGH MICRORNAS. THE EXPANSION IN FILARIAL GENOMICS WILL ALSO PROVIDE A SIGNIFICANT ENRICHMENT IN OUR KNOWLEDGE OF THE DIVERSITY AND VARIABILITY IN THE GENOMES OF THE ENDOSYMBIOTIC BACTERIUM WOLBACHIA LEADING TO A BETTER UNDERSTANDING OF THE GENETIC PRINCIPLES THAT GOVERN FILARIAL-WOLBACHIA MUTUALISM. THE GOAL HERE IS TO PROVIDE AN OVERVIEW OF THE TRENDS AND ADVANCES IN FILARIAL AND WOLBACHIA GENOMICS. 2012 18 5692 17 SILENCING OF LNCRNA PKIA-AS1 ATTENUATES SPINAL NERVE LIGATION-INDUCED NEUROPATHIC PAIN THROUGH EPIGENETIC DOWNREGULATION OF CDK6 EXPRESSION. NEUROPATHIC PAIN (NP) IS AMONG THE MOST INTRACTABLE COMORBIDITIES OF SPINAL CORD INJURY. DYSREGULATION OF NON-CODING RNAS HAS ALSO BEEN IMPLICATED IN THE DEVELOPMENT OF NEUROPATHIC PAIN. HERE, WE IDENTIFIED A NOVEL LNCRNA, PKIA-AS1, BY USING LNCRNA ARRAY ANALYSIS IN SPINAL CORD TISSUE OF SPINAL NERVE LIGATION (SNL) MODEL RATS, AND INVESTIGATED THE ROLE OF PKIA-AS1 IN SNL-MEDIATED NEUROPATHIC PAIN. WE OBSERVED THAT PKIA-AS1 WAS SIGNIFICANTLY UPREGULATED IN SNL MODEL RATS AND THAT PKIA-AS1 KNOCKDOWN ATTENUATED NEUROPATHIC PAIN PROGRESSION. ALTERNATIVELY, OVEREXPRESSION OF PKIA-AS1 WAS SUFFICIENT TO INDUCE NEUROPATHIC PAIN-LIKE SYMPTOMS IN UNINJURED RATS. WE ALSO FOUND THAT PKIA-AS1 MEDIATED SNL-INDUCED NEUROPATHIC PAIN BY DIRECTLY REGULATING THE EXPRESSION AND FUNCTION OF CDK6, WHICH IS ESSENTIAL FOR THE INITIATION AND MAINTENANCE OF NEUROINFLAMMATION AND NEUROPATHIC PAIN. THEREFORE, OUR STUDY IDENTIFIES PKIA-AS1 AS A NOVEL THERAPEUTIC TARGET FOR NEUROINFLAMMATION RELATED NEUROPATHIC PAIN. 2019 19 2649 20 EPIGENOMIC, GENOMIC, AND TRANSCRIPTOMIC LANDSCAPE OF SCHWANNOMATOSIS. SCHWANNOMATOSIS (SWNTS) IS A GENETIC CANCER PREDISPOSITION SYNDROME THAT MANIFESTS AS MULTIPLE AND OFTEN PAINFUL NEURONAL TUMORS CALLED SCHWANNOMAS (SWNS). WHILE GERMLINE MUTATIONS IN SMARCB1 OR LZTR1, PLUS SOMATIC MUTATIONS IN NF2 AND LOSS OF HETEROZYGOSITY IN CHROMOSOME 22Q HAVE BEEN IDENTIFIED IN A SUBSET OF PATIENTS, LITTLE IS KNOWN ABOUT THE EPIGENOMIC AND GENOMIC ALTERATIONS THAT DRIVE SWNTS-RELATED SWNS (SWNTS-SWNS) IN A MAJORITY OF THE CASES. WE PERFORMED MULTIPLATFORM GENOMIC ANALYSIS AND ESTABLISHED THE MOLECULAR SIGNATURE OF SWNTS-SWNS. WE SHOW THAT SWNTS-SWNS HARBOR DISTINCT GENOMIC FEATURES RELATIVE TO THE HISTOLOGICALLY IDENTICAL NON-SYNDROMIC SPORADIC SWNS (NS-SWNS). WE DEMONSTRATE THE EXISTENCE OF FOUR DISTINCT DNA METHYLATION SUBGROUPS OF SWNTS-SWNS THAT ARE ASSOCIATED WITH SPECIFIC TRANSCRIPTIONAL PROGRAMS AND TUMOR LOCATION. WE SHOW SEVERAL NOVEL RECURRENT NON-22Q DELETIONS AND STRUCTURAL REARRANGEMENTS. WE DETECTED THE SH3PXD2A-HTRA1 GENE FUSION IN SWNTS-SWNS, WITH PREDOMINANCE IN LZTR1-MUTANT TUMORS. IN ADDITION, WE IDENTIFIED SPECIFIC GENETIC, EPIGENETIC, AND ACTIONABLE TRANSCRIPTIONAL PROGRAMS ASSOCIATED WITH PAINFUL SWNTS-SWNS INCLUDING PIGF, VEGF, MEK, AND MTOR PATHWAYS, WHICH MAY BE HARNESSED FOR MANAGEMENT OF THIS SYNDROME. 2021 20 3598 14 IMPLICATIONS ON HYPNOTHERAPY: NEUROPLASTICITY, EPIGENETICS AND PAIN. WE PROVIDE A BRIEF REVIEW ABOUT THE SIGNIFICANCE OF HYPNOSIS WITH RESPECT TO APPLICATIONS AND PHYSIOLOGICAL PROCESSES IN HYPNOTHERAPY. OUR REVIEW CONCLUDES THAT HYPNOSIS IS A PROMISING METHOD TO MANAGE ACUTE AND CHRONIC PAIN. IN ADDITION, WE DISCUSS INDICATIONS POINTING TOWARD THE VIEW THAT HYPNOSIS CAN INDUCE CHANGES IN NEUROPLASTICITY POSSIBLY INVOLVING EPIGENETIC MECHANISMS. 2021